期刊文献+

米铂的合成工艺改进

Improved Synthetic Process of Miriplatin
原文传递
导出
摘要 本研究对米铂(1)的合成工艺进行了改进。十四烷酸(2)和氢氧化钠在乙酸乙酯/纯化水混合溶剂中反应,经静置析晶得十四烷酸钠(3)。3和奥沙利铂(4)在水中反应,经静置析晶、抽滤、热纯化水淋洗和精制后得1,纯度达99.91%,总收率79%(以2计),并且将1中3和草酸的含量均降至0.05%以下。优化后的工艺对原料2的质量要求降低:同系物十至十六烷酸单杂含量不超过0.2%,各杂质含量之和不超过1.0%即可得到合格产品,后处理简单,易于工业化生产。 The synthetic process of miriplatin(1)was improved.Tetradecanoic acid(2)reacted with NaOH in ethyl acetate/pure water and purified by static crystallization to give sodium tetradecanoate(3).Compound 3 reacted with oxaliplatin(4)in water to give crude 1,which was followed by standing for crystallization,suction filtration,hot pure water washing and refining to obtain the final product in a purity of 99.91%and a total yield of 79%(based on 2).The contents of both 3 and oxalic acid in 1 were less than 0.05%.The quality requirements for raw material 2 in this process for synthesis of the qualified product were decreased:the content of any individual impurity in the homologous(C10-C16 acids)was no more than 0.2%,and the total impurities were no more than 1.0%.The work-up was simple,and this process was more feasible for industrial production.
作者 褚延军 王春燕 刘戈 提文利 张贵民 CHU Yanjun;WANG Chunyan;LIU Ge;TI Wenli;ZHANG Guimin(National Engineering and Technology Research Center of Chirality Pharmaceutical,Lunan Pharmaceutical Group Co.,Ltd.,Linyi 273400)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2020年第4期484-486,531,共4页 Chinese Journal of Pharmaceuticals
关键词 米铂 十四烷酸钠 静置析晶 工艺优化 miriplatin sodium tetradecanoate static crystallization process improvement
  • 相关文献

参考文献2

二级参考文献18

  • 1OKUSAKA T,OKADA S,NAKANISHI T,et al.Phase Ⅱ trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative(SM-11355) in patients with hepatocellular carcinoma[J].Invest New Drugs,2004,22(2):169-176.
  • 2KISHIMOTO S,NOGUCHI T,YAMAOKA T,et al.In vitro release of SM-11355,cis-[((1R,2R)-1,2-cyclohexanediamine-N,N′) bis (myristato)]platinum(Ⅱ) suspended in lipiodol[J].Biol Pharm Bull,2000,23(5): 637-640.
  • 3HANADA M,BABA A,TSUTSUMISHITA Y,et al.Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis[J].Cancer Chemother Pharmacol,2009,64(3): 473-483.
  • 4FUJIYAMA S,SHIBATA J,MAEDA S,et al.Phase Ⅰ clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol[J].Br J Cancer,2003,89(9): 1614-1619.
  • 5KISHIMOTO S,NOGUCHI T,YAMAOKA T,et al.Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration[J].Biol Pharm Bull,2000,23(3): 344-348.
  • 6KISHIMOTO S,MIYAZAWA K,TERAKAWA Y,et al.Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis (myristato)]platinum(Ⅱ) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line[J].Jpn J Cencer Res,2000,91(12):1326-1332.
  • 7MAEDA M,SASAKI T.Liposoluble platinum (Ⅱ) complex and preparation thereof: EP,0193936(B1)[P].1986-03-05.
  • 8TANNO N,KISHIMOTO H,NAKATSU M.Fat soluble platinum (Ⅱ) complex hydrate: JP,11315088 A[P].1999-11-16.
  • 9YOKOYAMA T; KISHIMOTO H.Method for preparing platinum complex : JP,2004083508 A[P].2004-03-18.
  • 10KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. In vitro release of SM-11355, cis[ ( ( iR, 2R) -1,2-cyclohexanediamine-N, N') bis(myristato) ] platinum (II) suspended in lipiodol [ J 1. Biol Pharm Bull, 2000, 23 (5) : 637 - 640.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部